INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA
Instituto
Yale Cancer Center
New Haven, Estados UnidosPublicaciones en colaboración con investigadores/as de Yale Cancer Center (13)
2023
-
Improved benefit of continuing luspatercept therapy: sub-analysis of patients with lower-risk MDS in the MEDALIST study
Annals of Hematology, Vol. 102, Núm. 2, pp. 311-321
2022
-
Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk
Prostate Cancer and Prostatic Diseases, Vol. 25, Núm. 2, pp. 274-282
-
Improved Survival with Enzalutamide in Patients with Metastatic Hormone-Sensitive Prostate Cancer
Journal of Clinical Oncology, Vol. 37
2021
-
Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses
The Journal of urology, Vol. 205, Núm. 5, pp. 1361-1371
-
Reply by Authors
The Journal of urology, Vol. 205, Núm. 5, pp. 1371
2017
-
Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma
Cancer Medicine, Vol. 6, Núm. 1, pp. 36-44
2016
-
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment
Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557
2014
-
Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: Pivotal study update demonstrates durable responses
Journal of Hematology and Oncology, Vol. 7, Núm. 1
-
The IASLC/ITMIG thymic epithelial tumors staging project: Proposal for an evidence-based stage classification system for the forthcoming (8th) edition of the TNM classification of malignant tumors
Journal of Thoracic Oncology, Vol. 9, Núm. 9, pp. S65-S72
-
The IASLC/ITMIG thymic epithelial tumors staging project: Proposals for the N and M components for the forthcoming (8th) edition of the TNM classification of malignant tumors
Journal of Thoracic Oncology, Vol. 9, Núm. 9, pp. S81-S87
-
The IASLC/ITMIG thymic epithelial tumors staging project: Proposals for the T component for the forthcoming (8th) edition of the TNM classification of malignant tumors
Journal of Thoracic Oncology, Vol. 9, Núm. 9, pp. S73-S80
-
Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma
Biomarker Research, Vol. 2, Núm. 1
2012
-
Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy
Journal of Clinical Oncology, Vol. 30, Núm. 6, pp. 631-636